|L - Antineoplastic and Immunomodulating Agents|
This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
|L04 - Immunosuppressants|
Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.
|L04A - Immunosuppressants|
This group comprises immunosuppressants excl. corticosteroids.
The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.
|L04AB - Tumor Necrosis Factor Alpha (Tnf-Α) Inhibitors|
The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.
The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.
|L04AB02 - Infliximab|
|Dose||Route of administration||Note|
|3.75 mg||P|| |